Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00258310 · OUTCOME

Recurrence-free Survival

Ph II Long Term/Low Dose Xeloda in Head and Neck Squamous Cell Carcinoma After Surgery, Radiation & or Chemo · Source last updated 2023-03-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
Within 3 years of end of study.

What was measured

Time to recurrence or death

Analysis population: All enrolled participants

Groups in this outcome

Capecitabine

Capecitabine 1000mg/day for one year capecitabine adjuvant therapy

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Capecitabine34

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
CapecitabineNANot reportedNANAMedian was not reached due to insufficient number of participants with events
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        Median was not reached due to insufficient number of participants with events
        group Id
        OG000
        lower Limit
        NA
        upper Limit
        NA
        value
        NA
denoms
  1. counts
    1. group Id
      OG000
      value
      34
    units
    Participants
description
Time to recurrence or death
dispersion Type
95% Confidence Interval
groups
  1. description
    Capecitabine 1000mg/day for one year capecitabine adjuvant therapy
    id
    OG000
    title
    Capecitabine
param Type
MEDIAN
population Description
All enrolled participants
reporting Status
POSTED
time Frame
Within 3 years of end of study.
title
Recurrence-free Survival
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice